Dermatologists in New Zealand have highlighted a significant gap in the treatment of eczema, with many patients unable to access advanced therapies despite severe symptoms. Currently, the country is reportedly a decade behind global standards in eczema management, despite having one of the highest prevalence rates worldwide, affecting approximately 6 percent of the population.
Advanced treatments such as JAK inhibitors and biologics, designed to regulate the body’s immune response, have been transformative for some patients. One young man, previously unable to function normally due to severe eczema, described how starting the JAK inhibitor upadacitinib (Rinvoq) had dramatically improved his quality of life. However, these medications come at a high cost, often exceeding $30,000 annually, putting them out of reach for many who struggle to afford them.
Pharmac, New Zealand’s drug-funding agency, has shown interest in funding these treatments but faces challenges such as budget constraints and supply availability. Upadacitinib for moderate to severe eczema is currently under consideration, while the biologic dupilumab (Dupixent) awaits a supplier for the local market.
Dr. Michael Sawchuck, a dermatologist in Wellington, emphasizes the urgent need for these treatments, citing cases where patients cannot work or attend school due to their condition. Despite occasional approvals for special cases, securing funding remains arduous and time-consuming.
According to Dr. Scott Barker, incoming president of the Dermatological Society, New Zealand not only lacks access to advanced treatments but also suffers from a shortage of specialists who can prescribe them. With only 22 full-time dermatologists serving the public health system, the current ratio of specialists to patients is far below international standards, making it difficult for patients to receive timely and appropriate care.
Advocates within the Dermatological Society are pushing for reforms, including a “hub and spoke” model that would centralize specialized care and improve workforce capacity across the country. They are hopeful that ongoing discussions with Health Minister Shane Reti will lead to concrete steps to address these systemic issues.
In summary, while some progress has been made in advocating for advanced eczema treatments in New Zealand, significant challenges remain in ensuring equitable access and timely care for all affected individuals.
Related Topics:
